Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January
January 05, 2022 07:00 ET
|
Ocuphire Pharma
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial Initiated Enrollment of Nyxol MIRA-4 Pediatric Study in RM per Agreed Initial Pediatric Study Plan with FDA Nyxol MIRA-3 Phase 3 Results,...
Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330
December 08, 2021 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)
November 23, 2021 09:00 ET
|
Ocuphire Pharma
RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022 Nyxol has the Potential Opportunity to Address Estimated $500M+ Reversal of Dilation Market with No Approved...
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
November 12, 2021 07:00 ET
|
Ocuphire Pharma
On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol® Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial Data Readouts Expected in Early...
Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting
November 01, 2021 09:30 ET
|
Ocuphire Pharma
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative...
Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
October 07, 2021 07:00 ET
|
Ocuphire Pharma
New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related...
Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting
October 01, 2021 08:49 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
September 27, 2021 07:00 ET
|
Ocuphire Pharma
Benzinga Healthcare Small Cap Conference on September 29-30, 2021 Ophthalmology Futures Forums: European Virtual Forum on October 7, 2021 Alliance Global Partners Biotech & Specialty...
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2021 17:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed...
Ocuphire Pharma Presenting at Four Conferences in September
September 02, 2021 07:00 ET
|
Ocuphire Pharma
Euro Forums 2021 Virtual Retina Forum on September 8, 2021 HC Wainwright Virtual 23rd Annual Global Investment Conference on September 13-15, 2021 Oppenheimer Virtual Fall Healthcare Life...